RNA 治疗市场 - 按产品、类型、适应症、最终用途、全球预测，2024 年 - 2032 年

在癌症、遗传性疾病和传染病等慢性疾病盛行率不断上升的推动下，RNA 疗法市场规模预计在 2024 年至 2032 年间以 5.7% 的复合年增长率创纪录。根据美国国立卫生研究院(NIH) 的数据，2023 年，美国RNA 疗法出现了近1,958,310 例新癌症病例和609,820 例癌症死亡，这为透过针对特定基因和途径提供更有效和个性化的治疗方法来解决这些疾病提供了潜力。 RNA 递送技术（例如脂质奈米粒子和病毒载体）的进步正在增强基于 RNA 的药物的功效和安全性。

此外，围绕 RNA 疗法的监管环境正在不断发展，监管机构越来越认识到基于 RNA 的药物在简化审批流程方面的潜力。在基因组定序和分子诊断进步的推动下，个人化医疗方法的日益普及也为 RNA 疗法精确地针对特定患者群体创造了机会。随着全球医疗保健系统努力改善患者治疗效果并降低医疗成本，对创新和标靶治疗的需求预计将推动产业成长。

RNA 治疗市场根据产品、类型、适应症、最终用途和地区进行分类。

根据迹象，到 2032 年，自体免疫疾病领域的产业规模预计将达到 6% 的复合年增长率，其特征是针对人体自身组织的免疫反应失调。 RNA疗法透过针对参与免疫失调的特定分子途径，为治疗自体免疫疾病提供了一条有前景的途径。此外，基于RNA的技术的进步，例如反义寡核苷酸和小干扰RNA，能够精确调节与自体免疫疾病相关的基因表达，从而提供潜在的治疗益处。

就最终用途而言，学术和研究机构领域的RNA 治疗市场预计在2024 年和2032 年期间复合年增长率为5.4%。点并开发创新药物基于RNA的疗法。此外，学术和研究机构充当人才和创新的孵化器，培养下一代科学家和企业家，进一步推动该领域的成长。

亚太地区RNA治疗产业在2024年至2032年间将以6.1%的复合年增长率大幅成长，原因是人口众多且多样化，加上传染病和慢性病的高盛行率。以学术研究机构、生物製药公司和政府措施网络为特征的强大生物技术生态系统的存在正在促进 RNA 治疗领域的多项研发活动。此外，有利的监管政策以及对医疗基础设施和生物技术的投资增加将刺激区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 传染病发生率上升
    • RNA 递送技术的进步
    • 加强市场参与者之间的伙伴关係和合作
  • 产业陷阱与挑战
    • RNA治疗产品召回
    • 开发和製造成本高
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 疫苗
• 药品

第 6 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• mRNA疗法
• 反义寡核苷酸（ASO）疗法
• siRNA（小干扰RNA）疗法
• RNA 干扰 (RNAi) 疗法
• 其他类型

第 7 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 传染性疾病
• 遗传/遗传疾病
• 自体免疫疾病
• 其他适应症

第 8 章：市场估计与预测：依最终用途，2018 - 2032 年

• 医院
  • 私人的
  • 民众
• 学术及研究机构
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• BioNTech SE
• Ionis Pharmaceuticals
• Moderna Inc.
• Novartis AG
• Orna Therapeutics, Inc.
• Pfizer Inc.
• Sanofi
• Sarepta Therapeutics, Inc.

RNA therapeutics market size is set to record 5.7% CAGR of between 2024 and 2032, driven by the increasing prevalence of chronic disorders, such as cancer, genetic disorders, and infectious diseases. As per National Institutes of Health (NIH), in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the U.S. RNA therapeutics offer the potential to address these diseases by targeting specific genes and pathways for providing more effective and personalized treatment approaches. Advancements in RNA delivery technologies, such as lipid nanoparticles and viral vectors, are enhancing the efficacy and safety profile of RNA-based drugs.

Moreover, the regulatory landscape surrounding RNA therapeutics is evolving, with regulatory agencies increasingly recognizing the potential of RNA-based drugs for streamlining the approval process. The growing adoption of personalized medicine approaches, driven by advancements in genomic sequencing and molecular diagnostics is also creating opportunities for RNA therapeutics to target specific patient populations with precision. As healthcare systems worldwide strive to improve patient outcomes and reduce healthcare costs, the demand for innovative and targeted therapies is expected to bolster the industry growth.

The RNA therapeutics market is classified on the basis of product, type, indication, end-use and region.

Based on indication, the industry size from the autoimmune disorder segment is slated to record a 6% CAGR through 2032, characterized by dysregulated immune responses targeting the body's own tissues. RNA therapeutics offer a promising avenue for treating autoimmune diseases by targeting specific molecular pathways involved in immune dysregulation. Additionally, advancements in RNA-based technologies, such as antisense oligonucleotides and small interfering RNAs, enable precise modulation of gene expression associated with autoimmune disorders, thereby offering potential therapeutic benefits.

In terms of end-use, the RNA therapeutics market from the academic & research institutes segment is anticipated to observe a 5.4% CAGR during 2024 and 2032. This is driven by advancements in the understanding of RNA biology for uncovering novel therapeutic targets and developing innovative RNA-based therapies. Moreover, academic and research institutes serve as incubators for talent and innovation for nurturing the next generation of scientists and entrepreneurs, further propelling the segment growth.

Asia Pacific RNA therapeutics industry will grow substantially at 6.1% CAGR between 2024 and 2032, attributed to the large and diverse population coupled with the high prevalence of infectious and chronic diseases. The presence of a robust biotechnology ecosystem, characterized by a network of academic research institutions, biopharmaceutical companies, and government initiatives is fostering multiple R&D activities in RNA therapeutics. Furthermore, favorable regulatory policies and increasing investments in healthcare infrastructure and biotechnology will stimulate the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculation
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of infectious diseases
    • 3.2.1.2 Advancements in RNA delivery technologies
    • 3.2.1.3 Increasing partnerships and collaborations among market players
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Recall of RNA therapeutic products
    • 3.2.2.2 High cost of development and manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vaccines
• 5.3 Drugs

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 mRNA therapeutics
• 6.3 Antisense oligonucleotide (ASO) therapeutics
• 6.4 siRNA (small interfering RNA) therapeutics
• 6.5 RNA interference (RNAi) therapeutics
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Hereditary/genetic diseases
• 7.4 Autoimmune disorders
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Hospitals
  • 8.1.1 Private
  • 8.1.2 Public
• 8.2 Academic & research institutes
• 8.3 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alnylam Pharmaceuticals, Inc.
• 10.2 Arrowhead Pharmaceuticals, Inc.
• 10.3 BioNTech SE
• 10.4 Ionis Pharmaceuticals
• 10.5 Moderna Inc.
• 10.6 Novartis AG
• 10.7 Orna Therapeutics, Inc.
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Sarepta Therapeutics, Inc.